|
|
|
|
|
|
by ashdksnndck
335 days ago
|
|
|
23andMe’s new business model (Anne Wojcicki and Regeneron both had the same plan for it) is to use the data for drug development. That’s theoretically where the $$$$ is. Turns out you can use statistical association between genes and other biomarkers to discover drugs that will succeed in clinical trials. So, I suppose, if everyone could use the data, everyone could use it to develop drugs, not just 23andMe. That’s good if you want more drugs to be developed and released… bad if you don’t. |
|
|